INTRODUCTION {#s1}
============

Resistance to endocrine therapy is a major clinical problem for the management of estrogen receptor positive (ER+) breast cancers. ER+ tumors comprise 70% of all breast cancer cases. Antiestrogens such as tamoxifen, ICI 182,780/faslodex/fulvestrant (ICI) or aromatase inhibitors (AI) are widely used endocrine therapies but little is known about the complex cellular pathways that contribute to resistance \[[@R1], [@R2]\]. Deregulation of metabolic pathways regulated by oncogenes such as MYC has been implicated in endocrine resistant breast cancer \[[@R3]--[@R5]\]. However, to understand the systems-level changes in endocrine resistance, biologically relevant interactions between genes and metabolites need to be identified and validated. Using paired cell lines that are either sensitive or resistant to antiestrogens we generated and integrated data from transcriptomics (microarray analysis) and metabolomics (GC/MS and UPLC/MS). Within our gene-metabolite integrated model, we selected to further study the role of EGR1 (early growth response 1), a gene that is known to be deregulated in some cancers \[[@R6]\].

EGR1 is an immediate-early gene induced by estrogen, growth factors, or stress signals, and can exhibit both tumor suppressor and promoter activities. A nuclear phospho-protein and transcription factor that can promote cell proliferation and cell death \[[@R7], [@R8]\], EGR1 can be induced by external stimuli, with its induction being either transient or sustained. Such a diverse array of functions is achieved through differential regulation of EGR1 expression and its selection of target genes \[[@R7]\]. A highly conserved DNA-binding domain on EGR1 targets the GC-rich consensus sequence GCG (G/T) GGGCG. Transcriptional activity of EGR1 is further regulated by NAB-1 and NAB-2 (NGF-I A-binding proteins) \[[@R9], [@R10]\]. EGR1 can promote growth of some hormone regulated cancers including prostate cancer \[[@R11]\]. EGR1 mediated signaling is important for the normal development of female reproductive organs \[[@R12]\] but its precise role in breast cancer remains unclear. The EGR1 gene is deleted in some ER-negative breast tumors \[[@R13]\]. In ER+ breast cancer cells, EGR1 is induced by estrogen treatment following raf-1 kinase activation \[[@R14]\] and is inhibited with acquired resistance to ICI \[[@R15]\]. EGR1 has been associated with sensing cellular glucose levels \[[@R16], [@R17]\], in fatty acid metabolism and inflammation \[[@R18]\] in various cells. In this study, we investigated the role of EGR1 in endocrine resistance to validate an integrated model consisting of differentially expressed genes and metabolites in endocrine resistant breast cancer cells. Decreased levels of EGR1 in ER+ breast cancer cells and human tumors correlated with decreased sensitivity to antiestrogens. However, sustained inhibition of EGR1 with siRNA or tolfenamic acid (TOLE) suppressed the growth of endocrine resistant breast cancer cells and interacted synergistically with both 4-hydroxytamoxifen (hereafter referred to as TAM), major active metabolite of tamoxifen, and ICI in inhibiting cell proliferation. EGR1 inhibition also disrupted fatty acid metabolism in endocrine resistant cells. Overall, our gene-metabolite integrated model suggests a novel role for EGR1 in regulating cellular metabolism in endocrine resistant breast cancer.

RESULTS {#s2}
=======

Analysis and integration of transcriptomics and metabolomics data from endocrine sensitive and resistant breast cancer cell lines {#s2_1}
---------------------------------------------------------------------------------------------------------------------------------

Comparing LCC1 and LCC9 cell lines yielded 4,010 unique differentially expressed genes (DEGs), 46 unique m/z values for metabolites from the Metabolomics Shared Resources Core (MSRC) analysis conducted at Georgetown University Medical Center and 12 identified metabolites from the Metabolon analysis at an FDR threshold of 0.01 for the first two analyses, respectively; 0.05 for the third analysis. (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). A heatmap was generated using all differentially expressed genes. Data visualization by principal component analysis (PCA) analysis was performed for both the MSRC and Metabolon metabolome analyses. While there was inherent noise, LCC1 and LCC9 cells were clearly separated in both plots. Figure [1C](#F1){ref-type="fig"} shows the integrated network of differentially expressed genes and putative metabolites in LCC9 cells (endocrine resistant) using 300 DEGs, 46 unique m/z values for metabolites from the MSRC analysis and 11 identified metabolites from the Metabolon analysis. The genes and metabolites present in the integrated network are also presented in Table [1](#T1){ref-type="table"}. Based on our metabolomics analysis, glutamate and prostaglandin levels were significantly higher in LCC9 compared with LCC1 cells (log2 FC=1.522, *p*-value = 0.00011, *q*-value = 0.00574; respectively log2 FC=1.047, *p*-value = 0.00019, *q*-value = 0.00759). Estradiol and endothelin along with three genes (PTGS1, PTGS2 and GRM7) were added to the network based on predictions from the STITCH database.

![Analysis and integration of gene and metabolites in LCC1 (sensitive) and LCC9 (resistant) ER+ breast cancer cells\
(**A**) Heatmap: R package Limma was used for microarray analysis of LCC1 versus LCC9 data; significantly different genes were selected (*q*-value \< 0.1, fold change, FC \> 2) to plot the heatmap; there were 3-biological replicates. (**B**) Principal component analysis: PCA analysis performed for the transcriptomics and metabolomics datasets - MSRC and Metabolon. (**C**) Integration of differentially expressed genes and putative metabolites comparing LCC9 (resistant) and LCC1 (sensitive) cells. Metabolites are shown as rectangular nodes, and genes as ellipses. *Orange* nodes are over-expressed; *blue* nodes are under-expressed; darker color represents a higher fold change (FC). Lowest log2 FC = --5.66, highest log2 FC = 5.89. *Grey* nodes are those added into the network based on prediction by STITCH. Edge thickness increases with the confidence of the connection as predicted by STITCH. Gene-metabolite connections are shown in *grey* lines, gene-gene connections are shows as *purple* lines, and metabolite-metabolite connections are shown as gold lines. EGR1 is significantly decreased in LCC9 cells (log2 FC= --2.33).](oncotarget-08-96865-g001){#F1}

###### Genes and metabolites from integrated network (Figure [1C](#F1){ref-type="fig"})

  Name                  Expanded Name                        Type         Probe/Metabolite ID    log2 fold-change   *p*-value   *q*-value
  --------------------- ------------------------------------ ------------ ---------------------- ------------------ ----------- -----------
  ESR1                  ESR1                                 gene         205225_at              --4.036            2.36E-12    6.91E-09
  LGALS3                LGALS3                               gene         208949_s\_at           --3.232            4.4E-11     3.55E-08
  KITLG                 KITLG                                gene         211124_s\_at           --2.666            5.47E-08    4.43E-06
  SOCS3                 SOCS3                                gene         227697_at              --2.575            5.68E-10    1.96E-07
  EGR1                  EGR1                                 gene         201694_s\_at           --2.333            6.25E-08    4.88E-06
  IL1R1                 IL1R1                                gene         202948_at              --2.331            4.10E-08    3.71E-06
  ABAT                  ABAT                                 gene         209459_s\_at           --2.219            2.44E-08    2.53E-06
  STC2                  STC2                                 gene         203438_at              --2.176            3.24E-10    1.29E-07
  ABCG2                 ABCG2                                gene         209735_at              --2.133            7.61E-10    2.34E-07
  LFNG                  LFNG                                 gene         228762_at              --2.121            1.67E-09    4.12E-07
  ABCC3                 ABCC3                                gene         208161_s\_at           --2.061            4.81E-09    8.16E-07
  ERBB4                 ERBB4                                gene         214053_at              --1.884            6.01E-09    9.71E-07
  EDN1                  EDN1                                 gene         218995_s\_at           --1.823            2.36E-09    5.31E-07
  SLC12A2               SLC12A2                              gene         204404_at              --1.779            3.16E-09    6.38E-07
  GHR                   GHR                                  gene         205498_at              --1.734            2.62E-08    2.68E-06
  DLK1                  DLK1                                 gene         209560_s\_at           1.829              3.2E-09     6.41E-07
  CD36                  CD36                                 gene         206488_s\_at           1.906              4.86E-08    4.15E-06
  LGALS3BP              LGALS3BP                             gene         200923_at              2.065              3.38E-09    6.60E-07
  AOX1                  AOX1                                 gene         205083_at              2.14               3.54E-10    1.38E-07
  SLC7A11               SLC7A11                              gene         209921_at              2.231              1.77E-09    4.23E-07
  GNAI1                 GNAI1                                gene         227692_at              2.866              2.59E-10    1.19E-07
  EGR3                  EGR3                                 gene         206115_at              2.975              1.21E-08    1.55E-06
  RUNX2                 RUNX2                                gene         232231_at              3.02               4.77E-09    8.15E-07
  CYP2B6                CYP2B6                               gene         206754_s\_at           3.161              1.2E-10     6.69E-08
  DUSP4                 DUSP4                                gene         204014_at              4.272              4.56E-11    3.56E-08
  HPGD                  HPGD                                 gene         203913_s\_at           5.252              2.16E-10    1.08E-07
  GRM7                  GRM7                                 gene         Added to the network                                  
  PTGS1                 PTGS1                                gene                                                               
  PTGS2                 PTGS2                                gene                                                               
  docosapentaeno.       Docosapentaenoic acid (22N-6)        metabolite   HMDB01976              --1.911            0.00001     0.00141
  DGLA                  8;11;14-Eicosatrienoic acid          metabolite   HMDB02925              --0.938            0.00024     0.00859
  Mead_acid             5;8;11-Eicosatrienoic acid           metabolite   HMDB10378              --0.938            0.00024     0.00859
  lysine                Lysine                               metabolite   HMDB00182              0.872              0.00010     0.00521
  pyroglutamate         Pyroglutamic acid                    metabolite   HMDB00267              1                  0.00012     0.00586
  PGE1                  Prostaglandin E1                     metabolite   HMDB01442              1.047              0.00019     0.00759
  PGFM                  3,14-dihydro-15-keto PGF2a           metabolite   HMDB04685              1.047              0.00019     0.00759
  prostaglandin         Prostaglandin D1                     metabolite   HMDB05102              1.047              0.00019     0.00759
  NMDA                  N-Methyl-D-Aspartic acid             metabolite   HMDB02393              1.094              0.00006     0.00421
  dihydrodipicol.       L-2;3-Dihydrodipicolinate            metabolite   HMDB12247              1.094              0.00006     0.00421
  LysoPE\_(16:0/0.      LysoPE(16:0/0:0)                     metabolite   HMDB11503              1.294              0.00017     0.00712
  lysoPC                LysoPC (17:0/0.                      metabolite   HMDB12108              1.365              0.00002     0.00248
  L-valine              L-valine                             metabolite   HMDB00883              1.438              0.00013     0.00612
  alpha-(methyla.       alpha-(methylamino)isobutyric acid   metabolite   HMDB02141              1.438              0.00005     0.00399
  betaine               betaine                              metabolite   HMDB00043              1.438              0.00005     0.00399
  glutamate             glutamate                            metabolite   HMDB03339              1.522              0.00011     0.00574
  LysoPC\_(17:0/0.      LysoPC(17:0)                         metabolite   HMDB12108              1.795              0.00002     0.00248
  hydroxybutyrate^\*^   hydroxybutyrate                      metabolite   HMDB00710              1.297              0.00079     0.03740
  hypotaurine^\*^       Hypotaurine                          metabolite   HMDB00965              2.017              0.00001     0.00132
  endothelin            Endothelin                           metabolite   Added to the network                                  
  estradiol             Estradiol                            metabolite                                                         

The table shows the genes and metabolites from Figure [1C](#F1){ref-type="fig"}. The metabolite names are putative metabolites, so they could be one of the many annotations obtained. The metabolites marked with ^\*^ were from Metabolon and experimentally validated.

Results from the pathway analyses are presented in Table [2](#T2A){ref-type="table"}. Table [2A](#T2A){ref-type="table"} represents results using the significant metabolites, Table [2B](#T2B){ref-type="table"} using the top 300 genes, and Table [2C](#T2C){ref-type="table"} using both metabolites and genes. In particular, we noted the D-glutamine and D-glutamate metabolism pathway (Table [2A](#T2A){ref-type="table"}, *p*-value = 0.001, *q*-value = 0.052), several key signaling pathways (Table [2B](#T2B){ref-type="table"}, and prostaglandin synthesis and regulation (Table [2C](#T2C){ref-type="table"}, *p*-value \< 0.001, *q*-value = 0.002 when combining genes and metabolites).

###### Pathway analysis of significant metabolites (from MSRC and Metabolon) performed using MetaboAnalyst (<http://www.metaboanalyst.ca/>), showing pathways with *p*-value \< 0.05

  Name of pathway                          Number of significant metabolites in pathway / Number of metabolites in pathway   *p*-value   *q*-value
  ---------------------------------------- --------------------------------------------------------------------------------- ----------- -----------
  Arachidonic acid metabolism              7/62                                                                              \< 0.001    0.020
  D-Glutamine and D-glutamate metabolism   3/11                                                                              0.001       0.052
  Lysine degradation                       5/47                                                                              0.003       0.073
  Arginine and proline metabolism          6/77                                                                              0.005       0.101
  Sphingolipid metabolism                  3/25                                                                              0.015       0.237
  Glycerophospholipid metabolism           3/39                                                                              0.048       0.640

###### Pathway analysis of top 300 genes (according to *q*-value) using Reactome ([www.reactome.org](http://www.reactome.org)), showing pathways with *p*-value \< 0.05

  Name of pathway                                                                        Number of top genes in pathway/ Number of genes in pathway   *p*-value     *q*-value
  -------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------- -------------
  Translocation of ZAP-70 to Immunological synapse                                       16/39                                                        \< 1.00E-10   \< 1.00E-10
  Phosphorylation of CD3 and TCR zeta chains                                             16/44                                                        \< 1.00E-10   \< 1.00E-10
  PD-1 signaling                                                                         16/45                                                        \< 1.00E-10   \< 1.00E-10
  Generation of second messenger molecules                                               16/57                                                        \< 1.00E-10   \< 1.00E-10
  Co-stimulation by the CD28 family                                                      16/96                                                        \< 0.001      \< 0.001
  MHC class II antigen presentation                                                      18/141                                                       \< 0.001      \< 0.001
  Downstream TCR signaling                                                               16/123                                                       \< 0.001      \< 0.001
  Cytokine Signaling in Immune system                                                    41/747                                                       \< 0.001      \< 0.001
  Interferon Signaling                                                                   24/291                                                       \< 0.001      \< 0.001
  Interferon gamma signaling                                                             18/176                                                       \< 0.001      \< 0.001
  TCR signaling                                                                          16/145                                                       \< 0.001      \< 0.001
  ERBB2 Activates PTK6 Signaling                                                         4/18                                                         \< 0.001      0.026
  ERBB2 Regulates Cell Motility                                                          4/19                                                         \< 0.001      0.029
  Interleukin-19, 20, 22, 24                                                             3/9                                                          \< 0.001      0.035
  Downregulation of ERBB4 signaling                                                      3/10                                                         0.001         0.045
  SHC1 events in ERBB2 signaling                                                         4/25                                                         0.002         0.064
  Nuclear signaling by ERBB4                                                             5/44                                                         0.002         0.077
  Signaling by PTK6                                                                      6/80                                                         0.007         0.205
  GRB2 events in ERBB2 signaling                                                         3/20                                                         0.008         0.245
  Interferon alpha/beta signaling                                                        8/140                                                        0.009         0.252
  PTK6 Activates STAT3                                                                   2/7                                                          0.009         0.253
  PI3K events in ERBB2 signaling                                                         3/22                                                         0.011         0.273
  Termination of O-glycan biosynthesis                                                   3/28                                                         0.021         0.450
  Growth hormone receptor signaling                                                      3/29                                                         0.022         0.450
  Signaling by ERBB2                                                                     4/54                                                         0.026         0.450
  Activation of anterior HOX genes in hindbrain development during early embryogenesis   6/113                                                        0.030         0.450
  Activation of HOX genes during differentiation                                         6/113                                                        0.030         0.450
  Signaling by Interleukins                                                              15/425                                                       0.031         0.450
  Constitutive Signaling by Aberrant PI3K in Cancer                                      5/85                                                         0.032         0.450
  Adaptive Immune System                                                                 31/1075                                                      0.035         0.450
  Immune System                                                                          52/1984                                                      0.035         0.450
  RA biosynthesis pathway                                                                3/39                                                         0.047         0.450
  NCAM signaling for neurite out-growth                                                  11/300                                                       0.047         0.450
  ABC-family proteins mediated transport                                                 4/66                                                         0.048         0.450

###### Pathway analysis of top 300 genes (according to *q*-value) and significant metabolites using <http://impala.molgen.mpg.de/>

  Name of pathway                                                       Source of pathway   Pathway analysis for genes   Pathway analysis for metabolites   Pathway analysis for genes and metabolites                                      
  --------------------------------------------------------------------- ------------------- ---------------------------- ---------------------------------- -------------------------------------------- ------- ------- ------- ---------- -------
  Prostaglandin Synthesis and Regulation                                Wikipathways        4/28                         \< 0.001                           0.457                                        2/9     0.016   0.687   \< 0.001   0.002
  ABC-family proteins mediated transport                                Reactome            4/36                         \< 0.001                           0.457                                        2/10    0.019   0.746   \< 0.001   0.006
  Synthesis of Prostaglandins (PG) and Thromboxanes (TX)                Reactome            3/15                         \< 0.001                           0.457                                        3/34    0.038   1       \< 0.001   0.009
  Arachidonic acid metabolism                                           Reactome            3/54                         0.029                              1                                            7/78    0.001   0.096   \< 0.001   0.011
  Transmembrane transport of small molecules                            Reactome            15/594                       0.006                              0.63                                         9/178   0.014   0.618   \< 0.001   0.024
  Transport of inorganic cations/anions and amino acids/oligopeptides   Reactome            5/94                         0.006                              0.63                                         4/46    0.017   0.73    0.001      0.027
  GABA synthesis, release, reuptake and degradation                     Reactome            2/20                         0.025                              1                                            2/15    0.042   1       0.008      0.180

Decreased EGR1 expression correlates with decreased responsiveness to antiestrogens in human breast tumors {#s2_2}
----------------------------------------------------------------------------------------------------------

To determine whether EGR1 expression was associated with disease free survival, we used publicly available gene expression datasets (see Methods; Figure [2](#F2){ref-type="fig"}; Table [3](#T3){ref-type="table"}) for ER+ human breast tumors treated with endocrine therapy (adjuvant tamoxifen or AI as the only systemic therapy). Kaplan-Meier estimates of relapse-free survival over time (rfs_t) showed that high EGR1 gene expression levels were significantly correlated with favorable prognosis in at least two different datasets where breast tumors were treated with tamoxifen: in Symmans *et al.*, GSE17705 \[HR=0.38 (0.21--0.69); *p =* 0.00083\] \[[@R19]\] and Loi *et al.,* GSE6532 (ER+ samples on GPL96 platform) \[HR=0.62(0.4--0.95); *p =* 0.028\] \[[@R20]\] (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Furthermore, in Miller *et al.,* GSE20181 \[[@R21]\], pre-treatment versus 90 days post-treatment comparisons for treatment with the aromatase inhibitor Letrozole showed significantly increased levels of EGR1 expression (*p \<* 0.0001) only in the responder group (Figure [2C](#F2){ref-type="fig"}).

![Lower EGR1 levels correlate with lower survival in ER+ breast cancer patients treated with endocrine therapy\
(**A**) and (**B**) Kaplan-Meier plots were generated using the Symmans *et al.* and Loi *et al.* datasets to estimate the number of patients living over time post endocrine treatment (Tamoxifen) with indicated levels of EGR1 expression in their breast tumors; rfs_t (recurrence free survival time) (**C**) Pre-treatment vs. 90 days post-treatment (Letrozole) comparisons show significantly increased levels of EGR1 expression (*p \<* 0.0001) only in the responder group.](oncotarget-08-96865-g002){#F2}

###### Gene expression public dataset for ER+ breast cancer used for correlating EGR1 expression and endocrine response

  Dataset            Treatment   Duration                    Sample_Size
  ------------------ ----------- --------------------------- -----------------------
  Symmans *et al.*   Tamoxifen   5 years                     298
  Loi *et al.*       Tamoxifen   N/A                         181
  Miller *et al.*    Letrozole   0,10-14,90 day time-point   36 in each time-point

EGR1 regulates cell proliferation in both endocrine sensitive and resistant breast cancer cell lines {#s2_3}
----------------------------------------------------------------------------------------------------

To elucidate the role of EGR1 in endocrine responsiveness, we inhibited (RNAi) or overexpressed the EGR1 cDNA in LCC1 and LCC9 cells, followed by treatment with vehicle (ethanol), TAM, ICI or 17β-estradiol (E2). Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"} shows Western blot data that confirm the EGR1 protein levels with knockdown (EGR1-siRNA) or overexpression (EGR1-cDNA). Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"} show graphs of EGR1 protein levels normalized to actin protein levels from three independent experiments where LCC1 and LCC9 cells were transfected with either EGR1 siRNA, cDNA, or their respective controls. Under control conditions (control siRNA or empty vector/EV), the EGR1 protein levels were 1.25-fold higher in LCC1 cells compared with that in LCC9 cells. Thus, we confirmed the model prediction in Figure [1C](#F1){ref-type="fig"} that endogenous EGR1 expression is higher in LCC1 cells and lower in LCC9 cells. In EGR1 siRNA transfected cell, EGR1 protein levels decreased 2.5- and 3.8-fold in LCC1 and LCC9 cells, respectively, compared with control siRNA transfected cells. In EGR1 cDNA transfected cell, EGR1 protein levels increased 1.4-fold and 2.5-fold in LCC1 and LCC9 cells, respectively, compared to that in empty vector (EV) transfected cells. Independent of antiestrogen treatment, transfection with EGR1-siRNA significantly reduced cell proliferation in both cell lines within 48 h compared with control-siRNA (Figure [3D](#F3){ref-type="fig"}). To determine whether EGR1 siRNA changed cell viability, we studied changes in apoptosis and necrosis in LCC1 and LCC9 cells transfected with either control or EGR1 siRNA for 48 h. Figure [3E](#F3){ref-type="fig"} shows significant decrease in cell viability in both LCC1 and LCC9 cells transfected with control siRNA compared with EGR1 siRNA. Transfection with EGR1-cDNA did not initially affect LCC1 or LCC9 proliferation (Figure [3F](#F3){ref-type="fig"}). However, 5-days post-transfection, EGR1-cDNA transfected LCC1 and LCC9 cells each exhibited a significant decrease in proliferation compared with their respective EV-transfected controls (Figure [3G](#F3){ref-type="fig"}). LCC1 cells, at 5-days post-transfection with EGR1-cDNA and treated with ICI, showed a modestly additive growth inhibition relative to EV control cells. At 5-days post-transfection with EGR1-cDNA and E2 treatment, LCC1 cells showed a significant decrease in E2 response compared to their EV controls. Thus, some basal level of EGR1 protein expression may be essential for the survival of both endocrine sensitive and resistant cells, whereas changes beyond this base level in sensitive cells determines their responsiveness to E2.

![EGR1 expression regulate cell proliferation and viability in both endocrine sensitive and resistant ER+ breast cancer cells\
(**A**) Western blot of LCC1 and LCC9 cells showing the effect of EGR1 knockdown (EGR1-siRNA) and its respective control (EGR1-control-siRNA) or EGR1 overexpression (EGR1) or its respective control, empty vector (EV). Cells were transfected with siRNA or cDNA plasmid for 72 h. EGR1 protein appeared as a doublet, perhaps due to phosphorylation. Actin was used as a loading control. (**B**--**C**) Quantification of EGR1 protein (normalized to actin) following transfection with EGR1-siRNA compared with control siRNA in LCC1 and LCC9 cells show 2.5- and 3.8-fold reduction, respectively, (B) EGR1 protein in LCC1 and LCC9 cells show 1.4- and 2-fold increase, respectively, with EGR1-cDNA compared with EV, (**C**, **D**) EGR1 knockdown in both LCC1 and LCC9 cells significantly decreased cell proliferation at 48 h regardless of TAM or ICI treatment (ANOVA, *p \<* 0.001). (**E**) EGR1 knockdown significantly decreased cell viability in both LCC1 and LCC9 cells (ANOVA, *p \<* 0.01; ^\*^*p \<* 0.01 for cell death in EGR1-siRNA versus control-siRNA for respective cells lines) at 48 h. (**F**) and (**G**) EGR1 overexpression for 48 h followed by treatment with TAM or ICI for 3-days or 5-days, respectively. While EGR1 overexpression did not change cell proliferation of either LCC1 or LCC9 cell under control or treatment conditions at 3-days, at 5-days, EGR1 transfected LCC1 and LCC9 cells showed significant decrease in cell proliferation compared with respective cells transfected with EV. At 5-day transfection with EGR1 combined with E2 treatment showed a significant decrease in E2 response compared to EV control (ANOVA, *p \<* 0.05).](oncotarget-08-96865-g003){#F3}

EGR1 regulates fatty acid metabolism in endocrine resistant breast cancer cells {#s2_4}
-------------------------------------------------------------------------------

To determine the role of EGR1 in affecting cell metabolism in LCC9 cells, we transfected cells with either the EGR1-siRNA or control siRNA for 48 h, or with the EGR1 cDNA (EGR1-cDNA) and the respective EV controls. Five biological replicates were used for each group. Metabolomics analysis was performed by Metabolon. Data analysis followed the same steps as for the LCC1/LCC9 comparison. Negative correlation between the fold-changes from the two experiments indicated good global agreement between the knockdown and overexpression approaches (Figure [4](#F4){ref-type="fig"}). Applying an FDR cut off = 0.1 yielded 18 metabolites for the siRNA experiment; 15 of these metabolites had HMDB IDs (Table [4](#T4){ref-type="table"}). Pathway analysis of these 15 metabolites was done using MetaboAnalyst \[[@R22]\] and IMPaLA: Integrated Molecular Pathway Level Analysis \[[@R23]\] (Table [5](#T5){ref-type="table"}). No metabolites reached statistical significance for the EGR1 overexpression analysis. Several metabolites that were significantly regulated following EGR1 knockdown including 7-hydroxycholesterol and acetyl CoA, had fold-changes in the opposite direction when EGR1 was overexpressed.

![EGR1 knockdown in endocrine resistant cells disrupt fatty acid metabolism pathway\
Correlation between estimated log2 fold changes for the EGR1 knockdown experiment (siEGR1 vs. siCtrlEGR1) and the estimated log2 fold changes for the EGR1 siRNA experiment (EGR1 cDNA vs. EV EGR1). The negative correlation indicates agreement a global agreement between the two approaches, as the direction of change is expected to be different when comparing the knockdown to the overexpression experiments.](oncotarget-08-96865-g004){#F4}

###### Metabolites that were significantly altered with EGR1-siRNA knockdown in LCC9 cells, with *q*-value \< 0.1 with EGR1-siRNA versus EGR1-control siRNA in LCC9 cells

  Name                                               HDMB ID     KEGG ID   Results from siRNA experiment   Results from cDNA experiment                             
  -------------------------------------------------- ----------- --------- ------------------------------- ------------------------------ ------- --------- ------- -------
  stearoyl-arachidonoyl-glycerophosphoinositol (1)                         1.818                           \< 0.001                       0.097   --0.006   0.988   0.999
  1-arachidonoylglycerophosphoinositol               HMDB61690             2.829                           \< 0.001                       0.097   --0.060   0.865   0.999
  7-hydroxycholesterol (alpha or beta)                                     --3.116                         \< 0.001                       0.097   0.361     0.392   0.999
  desmosterol                                        HMDB02719   C01802    1.037                           \< 0.001                       0.097   --0.399   0.121   0.999
  N-acetylglucosamine                                HMDB00215   C00140    1.108                           0.002                          0.097   --0.418   0.216   0.999
  5-dodecenoate (12:1n7)                             HMDB00529             1.329                           0.002                          0.097   --0.220   0.522   0.999
  N-palmitoyl-sphingosine                            HMDB04949             1.415                           0.002                          0.097   0.141     0.648   0.999
  acetyl CoA                                         HMDB01206   C00024    --3.331                         0.002                          0.097   0.358     0.750   0.999
  dihomo-linolenate (20:3n3 or n6)                   HMDB02925   C03242    1.080                           0.002                          0.097   0.086     0.730   0.999
  linoleate (18:2n6)                                 HMDB00673   C01595    1.354                           0.003                          0.097   0.016     0.959   0.999
  erucate (22:1n9)                                   HMDB02068   C08316    1.172                           0.003                          0.097   0.234     0.454   0.999
  1-oleoylglycerophosphoserine                                             1.107                           0.003                          0.097   --0.062   0.893   0.999
  1-myristoylglycerol (1-monomyristin)               HMDB11561   C01885    1.937                           0.003                          0.100   --0.105   0.775   0.999
  nicotinamide ribonucleotide (NMN)                  HMDB00229   C00455    1.076                           0.004                          0.100   0.170     0.642   0.999
  phosphopantetheine                                 HMDB01416   C01134    2.875                           0.004                          0.100   0.070     0.952   0.999
  caprate (10:0)                                     HMDB00511   C01571    1.152                           0.004                          0.100   --0.122   0.693   0.999
  arachidonate (20:4n6)                              HMDB01043   C00219    1.019                           0.004                          0.100   0.176     0.493   0.999
  uridine 5'-diphosphate (UDP)                       HMDB00295   C00015    --1.032                         0.004                          0.100   --0.040   0.945   0.999

###### Pathway analysis on significant metabolites with EGR1-siRNA versus EGR1-control siRNA in LCC9 cells

  Name of pathway                                                                                  Source of pathway   Number of significant metabolites in pathway/ Number of metabolites in pathway   *p*-value   *q*-value
  ------------------------------------------------------------------------------------------------ ------------------- -------------------------------------------------------------------------------- ----------- -----------
  Biosynthesis of unsaturated fatty acids - Homo sapiens (human)                                   KEGG                4/32                                                                             \< 0.001    0.042
  Linoleic acid metabolism - Homo sapiens (human)                                                  KEGG                3/19                                                                             \< 0.001    0.042
  Signal Transduction                                                                              Reactome            6/169                                                                            \< 0.001    0.042
  Heparan sulfate/heparin (HS-GAG) metabolism                                                      Reactome            3/21                                                                             \< 0.001    0.042
  Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)   Reactome            2/5                                                                              \< 0.001    0.042
  Activation of Gene Expression by SREBP (SREBF)                                                   Wikipathways        2/5                                                                              \< 0.001    0.042
  YAP1- and WWTR1 (TAZ)-stimulated gene expression                                                 Wikipathways        2/5                                                                              \< 0.001    0.042
  Glycosaminoglycan metabolism                                                                     Wikipathways        3/27                                                                             \< 0.001    0.042
  Leishmaniasis - Homo sapiens (human)                                                             KEGG                2/6                                                                              \< 0.001    0.042
  Circadian Clock                                                                                  Wikipathways        2/6                                                                              \< 0.001    0.042
  triacylglycerol degradation                                                                      HumanCyc            3/29                                                                             \< 0.001    0.042
  Defective SLC26A2 causes chondrodysplasias                                                       Reactome            3/29                                                                             \< 0.001    0.042
  Defective PAPSS2 causes SEMD-PA                                                                  Reactome            3/29                                                                             \< 0.001    0.042
  Defective B4GALT7 causes EDS\_ progeroid type                                                    Reactome            3/29                                                                             \< 0.001    0.042
  Defective B3GAT3 causes JDSSDHD                                                                  Reactome            3/29                                                                             \< 0.001    0.042
  Defective CHSY1 causes TPBS                                                                      Reactome            3/29                                                                             \< 0.001    0.042
  Defective CHST3 causes SEDCJD                                                                    Reactome            3/29                                                                             \< 0.001    0.042
  Defective CHST14 causes EDS\_ musculocontractural type                                           Reactome            3/29                                                                             \< 0.001    0.042
  Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)                                                    Reactome            3/29                                                                             \< 0.001    0.042
  Defective CHST6 causes MCDC1                                                                     Reactome            3/29                                                                             \< 0.001    0.042
  Diseases associated with glycosaminoglycan metabolism                                            Reactome            3/29                                                                             \< 0.001    0.042
  Glycosaminoglycan metabolism                                                                     Reactome            3/29                                                                             \< 0.001    0.042
  Defective EXT2 causes exostoses 2                                                                Reactome            3/29                                                                             \< 0.001    0.042
  Defective EXT1 causes exostoses 1\_ TRPS2 and CHDS                                               Reactome            3/29                                                                             \< 0.001    0.042
  MPS IX - Natowicz syndrome                                                                       Reactome            3/29                                                                             \< 0.001    0.042
  MPS I - Hurler syndrome                                                                          Reactome            3/29                                                                             \< 0.001    0.042
  MPS II - Hunter syndrome                                                                         Reactome            3/29                                                                             \< 0.001    0.042
  MPS IIIA - Sanfilippo syndrome A                                                                 Reactome            3/29                                                                             \< 0.001    0.042
  MPS IIIB - Sanfilippo syndrome B                                                                 Reactome            3/29                                                                             \< 0.001    0.042
  MPS IIIC - Sanfilippo syndrome C                                                                 Reactome            3/29                                                                             \< 0.001    0.042
  MPS IIID - Sanfilippo syndrome D                                                                 Reactome            3/29                                                                             \< 0.001    0.042
  MPS IV - Morquio syndrome A                                                                      Reactome            3/29                                                                             \< 0.001    0.042
  MPS IV - Morquio syndrome B                                                                      Reactome            3/29                                                                             \< 0.001    0.042
  MPS VI - Maroteaux-Lamy syndrome                                                                 Reactome            3/29                                                                             \< 0.001    0.042
  MPS VII - Sly syndrome                                                                           Reactome            3/29                                                                             \< 0.001    0.042
  Mucopolysaccharidoses                                                                            Reactome            3/29                                                                             \< 0.001    0.042
  phospholipases                                                                                   HumanCyc            3/30                                                                             \< 0.001    0.044
  sphingomyelin metabolism/ceramide salvage                                                        HumanCyc            3/30                                                                             \< 0.001    0.044
  sphingosine and sphingosine-1-phosphate metabolism                                               HumanCyc            3/36                                                                             \< 0.001    0.063
  the visual cycle I (vertebrates)                                                                 HumanCyc            3/36                                                                             \< 0.001    0.063
  Transport of fatty acids                                                                         Reactome            2/9                                                                              \< 0.001    0.070
  Transcriptional Regulation of White Adipocyte Differentiation                                    Wikipathways        2/9                                                                              \< 0.001    0.070
  Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)   Wikipathways        2/9                                                                              \< 0.001    0.070

The pathway analysis was performed using tool <http://impala.molgen.mpg.de/> . The pathways enriched at *q*-value \< 0.1 are shown.

Results from the siRNA and cDNA experiments suggest that disrupted EGR1 expression may have a subtle impact on the metabolic profile of LCC9 breast cancer cells. However, since cell proliferation was significantly reduced in with EGR1-siRNA (at 48 h; Figure [3B](#F3){ref-type="fig"}) and with EGR1-cDNA (at 5-days; Figure [3D](#F3){ref-type="fig"}), these seemingly subtle metabolic changes at 48 h post-transfection likely underestimate their ability to affect cell phenotype.

Pathway analysis using the significant metabolites from the siRNA experiment is presented in Table [5](#T5){ref-type="table"}. Two of the pathways implicate fatty acid metabolism (biosynthesis of unsaturated fatty acids, transport of fatty acids). Fatty acids are a critical source of energy for mitochondrial oxidation and cellular ATP generation. Silencing of EGR1 was accompanied by high levels of glycerol and multiple monoacylglycerols such as 1-myristoylglycerol that may reflect an increase in complex lipid hydrolysis. Consequently, long chain fatty acids such as palmitoleate and medium chain fatty acids including caprylate and heptanoate were also elevated compared to control-siRNA cells. Fatty acid availability may ultimately alter mitochondrial β-oxidation.

TOLE down-regulates EGR1 and sensitizes resistant cells to antiestrogens {#s2_5}
------------------------------------------------------------------------

Since EGR1 is an essential regulator of cell survival, we tested the effect of TOLE, a nonsteroidal anti-inflammatory drug (NSAID) that induced cell death in an EGR1-dependent manner in colorectal cancer cells \[[@R24]\]. Western blot analysis of whole cell lysates from LCC1 cells (Figure [5A](#F5){ref-type="fig"}, left panel) show decreased levels of EGR1 at 48 h following treatment with 100 nM TAM or ICI, or 50 µM TOLE. In LCC9 cells (Figure [5A](#F5){ref-type="fig"}, right panel), treatment with TAM and ICI increased EGR1 protein levels at 72 h compared with control cells. TOLE treatment decreased EGR1 levels in LCC9 cells. In both LCC1 and LCC9 cells, co-treatment with TOLE and either TAM or ICI decreased EGR1 levels. In LCC1 cells, treatment with 100 nM TAM or ICI alone significantly (*p \<* 0.001) inhibited cell number; a combination of 50 µM TOLE and TAM or ICI significantly (*p \<* 0.001) decreased cell number compared with the individual treatments but the interaction was not synergistic (Figure [5B](#F5){ref-type="fig"}). In LCC9 cells, treatment with TAM or ICI had no effect on cell number compared with vehicle, but TOLE treatment alone (*p \<* 0.001) or in combination with either TAM (RI = 1.31; *p \<* 0.001) or ICI (RI = 1.20; *p \<* 0.001) synergistically reduced the number of cells within 72 h, implying a partial restoration of ICI sensitivity. To confirm that inhibition of cell number with TOLE was mediated through EGR1 downregulation, we treated LCC9 cells that were either transfected with control siRNA or EGR1 siRNA followed by treatment with increasing doses of TOLE (0--50 µM). EGR1 knockdown resulted in a significant decrease in TOLE-mediated inhibition in cell number at 25 and 50 µM (*p \<* 0.05; Figure [5C](#F5){ref-type="fig"}). Together, these data indicate that antiestrogen treatment can differentially affect EGR1 levels in endocrine sensitive versus resistant cells. Furthermore, TOLE can downregulate EGR1 levels and re-sensitize endocrine resistant cells to antiestrogens.

![TOLE decreased EGR1 protein in both sensitive and resistant cells and re-sensitize resistant cells to antiestrogens\
(**A**) Western blot analysis of LCC1 and LCC9 cells, treated with vehicle, TOLE (50 μM), TAM (100 nM) or ICI (100 nM) or the combination for 72 h. In LCC1 cells, TOLE, TAM or ICI treatment decreased EGR1 protein levels. However, in LCC9 cells, antiestrogens increased but TOLE deceased EGR1 protein levels. Actin was used as a loading control. (**B**) Cell proliferation was significantly decreased in both LCC1 and LCC9 with treatment with TOLE at 72 h. Combination of TAM or ICI with TOLE did not show a significant interaction in LCC1 cells. However, cell proliferation was synergistically decreased in LCC9 cells treated with TOLE +TAM (RI = 1.31) or ICI+TOLE (RI = 1.20) within 72 h. ANOVA, *p \<* 0.001; [\*](#FN1){ref-type="author-notes"}*p \<* 0.001 for specified treatment and cell line compared to vehicle. Dashed line denotes decrease in relative cell proliferation in each cell line with TOLE alone. (**C**) In LCC9 cells, knockdown of EGR1 with siRNA showed significant decrease in cell proliferation with 25 or 50 µM TOLE in LCC9 cells suggesting that TOLE-mediated EGR1 downregulation contributes to TOLE-induced decrease in cell proliferation in LCC9 cells. ANOVA, *p \<* 0.05; ^\*^*p \<* 0.05 for indicated concentration of TOLE in control-siRNA versus EGR1-siRNA.](oncotarget-08-96865-g005){#F5}

DISCUSSION {#s3}
==========

Molecular adaptations that lead to drug resistance in cancer cells are largely dependent on cellular context and the nature of the stress signal. To determine the pathways that promote endocrine resistance, we integrated gene expression data with metabolite concentrations studying only those signals that were significantly changed in resistant breast cancer cells (LCC9) compared with sensitive cells (LCC1). The resulting model implicated EGR1 as a gene that is downregulated in endocrine resistant cells and proposed an increased activation of the glutamine and arachidonic pathways (Figure [1C](#F1){ref-type="fig"}; Tables [2](#T2A){ref-type="table"} and [3](#T3){ref-type="table"}). Interestingly, pathway analysis of top DEGs showed that a number of pathways associated with immune response were significantly altered in endocrine resistant LCC9 cells. It is still unclear how immune response genes are regulated in ER+ breast cancer cells and tumors. In breast cancer patients, depression in cellular immunity was associated with resistance to endocrine therapy \[[@R25]\]. *In vivo* models of mammary tumors suggest a role of immune-associated genes in antiestrogen resistance \[[@R26], [@R27]\]. The signaling interactions between cancer cells and the tumor microenvironment remain to be elucidated. In this study, to validate our gene-metabolite integration model, we tested whether alteration of EGR1, which is down-regulated in LCC9 cells \[[@R15]\], changed endocrine responsiveness or survival in resistant cells. We also asked whether gene expression data from human tumors treated with endocrine therapy showed a correlation between higher EGR1 levels and a more favorable prognosis (Figure [2A](#F2){ref-type="fig"}).

EGR1 levels are high in some prostate cancers \[[@R28], [@R29]\], Wilm's tumors \[[@R30]\], and melanoma cells bearing oncogenic B-RAF mutation \[[@R31]\] compared to normal tissue. An array of stress stimuli including radiation, chemotherapy, or hypoxia can alter EGR1 levels and the nature of a response is determined by whether EGR1 transcriptionally up- or down-regulates specific target genes \[[@R6], [@R7], [@R32]\]. While the precise role of EGR1 in cell survival remains unclear, disruption of endogenous levels of EGR1 can either inhibit growth or promote tumor progression \[[@R33], [@R34]\]. In prostate cancer cell lines, EGR1 inhibition decreased cell growth, induced apoptosis \[[@R35]\], and decreased expression of the pro-inflammatory chemokine interleukin 8 (IL8) in a NF-κB-dependent pathway \[[@R36]\]. EGR1 has been implicated in the acquisition of resistance to hormone therapy particularly through its role in the androgen receptor (AR) pathway \[[@R37], [@R38]\]. In breast cancer, the role of EGR1 remains ambiguous. In an ER+, carcinogen-induced (7,12-dimethylbenz(a) anthracene; DMBA), rat mammary tumor model, EGR1 levels in tumors were reduced relative to normal mammary tissues but then increased with TAM treatment \[[@R39]\]. In ER-negative breast cancer, the EGR1 gene is frequently deleted \[[@R13]\]. Disruption of the ER signaling pathway can affect EGR1 levels in ER+ breast cancer cells and tumors \[[@R14], [@R39]\]. Interestingly, overexpression of EGR1 dramatically reduced E2-mediated proliferation in these cells. In a model to identify topological and temporal effects of E2 regulatory networks in MCF7 cells, EGR1 was identified as a mediator of some of the late responses to E2 \[[@R40]\]. Thus, EGR1 levels in breast cancer cells may be closely regulated by a functional ER pathway.

A role for EGR1 in regulating cellular metabolic pathways has been reported in several disease models including cancer. Several cellular metabolic pathways were altered with perturbation of EGR1 levels in LCC9 cells (Table [5](#T5){ref-type="table"}), particularly molecules associated with fatty acid metabolism. EGR1 and the lipogenic enzyme fatty acid synthase (FASN) are elevated in tissues adjacent to prostate cancer; this relationship is used as a predictive marker of recurrence \[[@R41]\]. FASN activation is required for estrogen-mediated signaling in ER+ breast cancer cells \[[@R42]\] . EGR1 is an immediate-early prostaglandin E2 (PGE2) target gene that can mediate eicosanoid regulation of genes involved in the immune and inflammatory responses \[[@R43]\]. Together, these findings highlight the critical role of EGR1 in fatty acid metabolism.

In LCC9 cells, combining TOLE and antiestrogens synergistically inhibited cell growth (Figure [5B](#F5){ref-type="fig"}). TOLE can inhibit synthesis of prostaglandins and has been used for treating migraines \[[@R44]\]. In a triple-negative breast cancer xenograft model, treatment with TOLE resulted in a significant reduction in tumor volume over 5 weeks compared to treatment with vehicle alone \[[@R45]\]. TOLE can inhibit cell growth in cancer cells through cyclooxygenase-independent pathways including inhibition of ErbB2 expression \[[@R46]\], activation or ATF3 \[[@R47]\], or induction of NSAID-activated gene-1 (NAG-1) \[[@R48]\] and EGR1 \[[@R24]\]. Contrary to the latter study, in our breast cancer cells, treatment with TOLE inhibited EGR1 protein levels in LCC9 cells and synergized with ICI and TAM (Figure [5B](#F5){ref-type="fig"}). Thus, cellular context is likely a key determinant of the outcomes of EGR1 action.

Overall, we present a comprehensive model incorporating the differential expression/concentration of genes and metabolites that may interact to determine breast cancer cell fate in the response to select endocrine therapies. We tested our model by further elucidating the role of EGR1 in endocrine sensitive and resistant breast cancer cells. Our data suggest that although EGR1 levels are significantly reduced in endocrine resistant cells, it is an essential driver of cell survival and metabolic pathways such as fatty acid metabolism. Targeting EGR1 with TOLE may be an effective therapeutic strategy in some endocrine resistant breast cancers. Furthermore, EGR1 levels in human breast tumors may be useful as a favorable prognosis marker in ER+ breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Cell culture and reagents {#s4_1}
-------------------------

LCC1 (sensitive) and LCC9 (ICI resistant and TAM cross-resistant) cells were established as previously described \[[@R49]--[@R51]\]. Cells were grown in phenol red--free IMEM (Life Technologies, Grand Island, NY; A10488-01) with 5% charcoal-stripped calf serum (CCS); this media contains 2 mM L-glutamine and ∼12 mM glucose. ICI182,780 (ICI) and 4-hydroxytamoxifen (TAM) were obtained from Tocris Bioscience (Ellisville, MO). Tolfenamic acid (TOLE) was purchased from Selleck (Houston, TX). All cells were authenticated by DNA fingerprinting and tested regularly for *Mycoplasma* infection. All other chemicals were purchased from Sigma-Aldrich.

Cell proliferation and viability {#s4_2}
--------------------------------

For determination of cell density, cells were plated in 96-well plates at 5 × 10^3^ cells/well. At 24 h, cells were treated with specified drugs for 48 h (or otherwise indicated). After treatment, media were removed, and plates were stained with a solution containing 0.5% crystal violet and 25% methanol, rinsed, dried overnight, and re-suspended in citrate buffer (0.1 M sodium citrate in 50% ethanol). Intensity of staining, assessed at 570 nm and quantified using a V~Max~ kinetic microplate reader (Molecular Devices Corp., Menlo Park, CA), is directly proportional to cell number \[[@R50], [@R51]\]. For assessing cell viability and cell death (apoptosis and necrosis), cells were treated for 48 h, and stained with an Annexin V-fluorescein isothiocyanate and propidium iodide, respectively (Trevigen, Gaithersburg, MD).

Transfections with EGR1 siRNA or cDNA {#s4_3}
-------------------------------------

Cells were plated at 60--80% confluence. EGR1 (10 nM of 3 unique 27mer siRNA duplexes; Origene, Rockville, MD) or their respective control siRNA, were transfected using the RNAiMAX (Invitrogen) transfection reagent. For EGR1 overexpression, EGR1 cDNA (catalog \#SC128132) was purchased from Origene and transfected with TransIT-2020 (Mirus). Cells were lysed at 48 h post-transfection and subjected to Western blot analysis or cell number assay as described above. Antiestrogens, 100 nM ICI or TAM, or vehicle (0.02% ethanol) was added to the transfected cells at 24 h and treatment was allowed for the time-points indicated. For 5-day treatments, cells were re-treated with the indicated drugs in fresh cell culture media at day 3.

Western analyses {#s4_4}
----------------

Total protein (∼20 μg) was isolated from cells following 72 h treatment or vehicle control (0.02% DMSO or ethanol) for protein analysis as previously described \[[@R50], [@R51]\]. The following antibodies were used: EGR1 (Cell Signaling, Danvers, MA), and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA).

Generation and integration of transcriptomic and metabolomic data from LCC1 and LCC9 cells {#s4_5}
------------------------------------------------------------------------------------------

### Transcriptome data {#s4_5_1}

We obtained and analyzed gene expression and untargeted metabolomics data from antiestrogen sensitive (LCC1) or antiestrogen resistant (LCC9). Microarray analysis was performed using three biological replicates from LCC1 and three biological replicates from LCC9 using Affymetrix HG U133 Plus 2.0 microarray at our Genomics and Epigenomics Shared Resources. Briefly, total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA). RNA labeling and hybridization were performed according to the Affymetrix protocol for one-cycle target labeling. For each experiment, fragmented cRNA was hybridized in triplicates to Affymetrix GeneChip HG-U95 arrays (Affymetrix, Santa Clara, CA). Affymetrix data analysis included pre-processing of the probe-level Affymetrix data (CEL files).

Metabolomics data {#s4_6}
-----------------

Metabolomics analysis was two-part: we sent cell samples to both our in-house MSRC and to Metabolon Inc. MSRC samples were five biological replicates from each of the two groups, each with two technical replicates. Metabolon samples were six biological replicates from each of the two groups. LC-MS was used to analyze the MSRC samples; both LC-MS and GC-MS were used by Metabolon.

For the MSRC protocol, metabolite extraction was performed as described by Sheikh *et al.* \[[@R52]\]. Briefly, the residual pellet was resuspended in 200 μL of solvent A (98% water, 2% ACN and 0.1% formic acid) for Ultra-performance liquid chromatography-electro-spray ionization quadrupole-time-of-flight mass spectrometry (UPLC-ESI-Q-TOFMS) analysis. Mass spectrometry was performed on a Q-TOF Premier (Waters) operating in either negative-ion (ESI-) or positive-ion (ESI+) electro-spray ionization mode with a capillary voltage of 3200 V and a sampling cone voltage of 20 V in negative mode and 35 V in positive mode. The cone gas flow was 25 L/h, and the source temperature was 120°C. Accurate mass was maintained by introduction of LockSpray interface of sulfadimethoxine (311.0814 \[M+H\]+ or 309.0658 \[M-H\]−). Data were acquired in centroid mode from 50 to 850 m/z in MS scanning. Centroided and integrated mass spectrometry data from the UPLC-TOFMS was processed to generate a multivariate data matrix using MarkerLynx (Waters).

For Metabolon, samples were prepared using the automated MicroLab STAR^®^ system (Hamilton Company, Reno, NV). A recovery standard was added prior to the first step in the extraction process for quality control (QC) purposes. Proteins were precipitated with methanol to remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites. The resulting extract was divided into five fractions: one for analysis by UPLC-MS/MS with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode electrospray ionization, one for LC polar platform, one for analysis by GC-MS, and one sample was reserved for backup. Samples were placed briefly on a TurboVap^®^ (Zymark) to remove the organic solvent. For LC, the samples were stored overnight under nitrogen before preparation for analysis. For GC, each sample was dried under vacuum overnight before preparation for analysis. The LC/MS portion of the platform was based on a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The MS analysis alternated between MS and data-dependent MS2 scans using dynamic exclusion, and the scan range was from 80--1000 m/z. The samples destined for analysis by GC-MS were were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization (EI) and operated at unit mass resolving power. The scan range was from 50--750 m/z. Raw data files are archived and extracted as described below. The scope of the Metabolon LIMS system encompasses sample accessioning, sample preparation and instrumental analysis and reporting and advanced data analysis. It has been modified to leverage and interface with the MSRC information extraction and data visualization systems, as well as third party instrumentation and data analysis software.

Metabolite quantification and data normalization {#s4_7}
------------------------------------------------

For the MSRC metabolomics data, peaks were detected and quantified using the estimated area-under-the-curve of the LC/MS signals via the CentWave algorithm \[[@R53]\]. For the Metabolon data, an in-house software was used for detection and integration of peaks \[[@R54]\]. For studies spanning multiple days, a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences. Essentially, each compound was corrected in run-day blocks by registering the medians to equal one (1.00) and normalizing each data point proportionately (termed the 'block correction'). For studies that did not require more than one day of analysis, no normalization was necessary, other than for data visualization. In certain instances, biochemical data were normalized to an additional factor (such as cell counts, total protein as determined by Bradford assay, osmolality) to account for differences in metabolite levels due to differences in the amount of material present in each sample.

Data analysis and integration of transcriptomics and metabolomics {#s4_8}
-----------------------------------------------------------------

Gene expression raw data were processed using the RMA algorithm as implemented in the R affy package \[[@R55]\], followed by a log2-transformation and analysis using a moderated *t*-test via the limma approach implemented in the limma package in Bioconductor \[[@R56]\]. MSRC metabolomics data were processed using the XCMS approach \[[@R53], [@R57], [@R58]\]. Internal controls were used to standardize raw values. Intensity values were then log2-transformed and quantile normalized \[[@R59]\], to avoid infinite value produced by 0 expression level during the log2-transform phase, 1e-06 was introduced to replace all 0 in the expression profile and the two technical replicates were averaged. Putative isotopes were identified via the CAMERA package \[[@R60]\] and higher-weight isotopes removed. Finally, results were analyzed using limma along with surrogate variable analysis \[[@R61], [@R62]\] to remove sources of variability unrelated to the comparison of interest. Metabolon data were processed by Metabolon as described above and log2-transformed, followed by the use of limma. Log2 transformation was performed for both data types to meet the normality assumptions for *t*-tests. All statistical tests were adjusted for multiple testing using the Benjamini-Hochberg approach to control the false discovery rate (FDR). Results are presented as both the *p*-values and the *q*-values (transformed *p*-values used for FDR control).

Metabolites significant at an FDR of \< 0.01 and \< 0.05 for the MSRC set and the Metabolon set, respectively, were annotated using the HMDB and Metlin databases \[[@R63], [@R64]\]. Pathway analyses for the genes significant at FDR of \< 0.01 were performed using Pathway Studio (<http://www.elsevier.com/online-tools/pathway-studio>) and Enrichr \[[@R65]\] that allowed us to perform pathway analysis using the KEGG \[[@R66]\] and Reactome \[[@R67]\] databases. Pathway analyses for the top metabolites significant at an FDR of \< 0.01 for our MSRC analysis and \< 0.05 for the Metabolon analysis were performed using MetaboAnalyst \[[@R22]\] and IMPaLA: Integrated Molecular Pathway Level Analysis \[[@R23]\], respectively.

The top 300 DEGs according to their *q*-value were chosen for integration, along with the metabolites obtained after the filtering described above. Knowledge-based integration of these gene expression and metabolomics results was performed using STITCH \[[@R68]\]. This created a network of genes and metabolites using text mining and database curation sources. Based on the information obtained from these sources, each connection was given a confidence value. For our network, connections with at-least medium confidence were selected \[[@R68], [@R69]\]. STITCH lists up to 50 articles that support each connection in the network. For each article, the PubMed ID and abstract was provided and the information therein was compared for consistency/relevance to the model solution. STITCH added nodes (genes or metabolites) to the predicted network to indicate an indirect connection between two input nodes. A network was created using the nearest 5 and nearest 10 interactions of the input genes and metabolites. The final network obtained in STITCH was downloaded, and formatted using Cytoscape \[[@R70]\] to overlay fold change values from our experiments and to visualize the network.

For EGR1 inhibition and overexpression experiments, five biological replicates were considered and the analysis was performed by Metabolon. The data analysis followed the same steps as that described above for the LCC1/LCC9 comparison. A relaxed FDR cut off of 0.1 was applied for each experiment. Since transfection with EGR1 siRNA in LCC9 cells resulted in significant reduction in cell proliferation at 48 h, the small metabolic changes at this time-point are likely sufficient to affect cell phenotype. The metabolites showing significant differences between the control group and the inhibition or overexpression group were considered in pathway analyses.

Estimates of relapse-free survival and EGR1 gene expression levels from public gene expression datasets {#s4_9}
-------------------------------------------------------------------------------------------------------

Publicly available datasets for gene expression from human ER+ breast cancer tumors that were treated with endocrine therapy were obtained: GSE17705 (Symmans *et al.,* treated with Tamoxifen) \[[@R19]\], GSE6532, ER+ samples on GPL96 platform (Loi *et al.*, treated with Tamoxifen) \[[@R20]\] and GSE20181 (Miller *et al.,* treated with Letrozole) \[[@R21]\]. Kaplan-Meier plots were generated using the Symmans *et al.* and Loi *et al.* datasets to estimate the number of patients living over time post endocrine treatment with indicated levels of EGR1 expression in their breast tumors. The dataset in Miller *et al.* was used to generate box plots to show difference in EGR1 expression in responders. Graphs were generated using tools in the R statistical programming language.

Statistical analysis for cell proliferation experiments {#s4_10}
-------------------------------------------------------

Statistical analyses were performed using the Sigmastat software package (Jandel Scientific, SPSS, Chicago, IL). Where appropriate, cell growth under different conditions were compared using ANOVA with a *post hoc t*-test for multiple comparisons. Differences were considered significant at *p* ≤ 0.05. Nature of interaction between TOLE, TAM and ICI was defined by measuring the R-index (RI). The RI values were obtained by calculating the expected cell survival (S~exp~; the product of survival obtained with drug A alone and the survival obtained with drug B alone) and dividing S~exp~ by the observed cell survival in the presence of both drugs (S~obs~). S~exp~/S~obs~ \> 1.0 indicates a synergistic interaction \[[@R71]\].
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AI

:   aromatase inhibitors

DEG

:   differentially expressed genes

EGR1

:   early growth response 1

E2

:   17β-estradiol

ER

:   estrogen receptor

EV

:   empty vector

ICI

:   ICI182,780

MSRC

:   Metabolomics Shared Resources Core

PCA

:   principal component analysis

TAM

:   4-hydroxytamoxifen

TOLE

:   Tolfenamic acid
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